Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Streptavidin（SA） Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Her2

Her2

Brief Information

Name:Receptor protein-tyrosine kinase erbB-2
Target Synonym:EC 2.7.10,EC:2.7.10.1,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (Neuro/Glioblastoma Derived Oncogene Homolog),V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2,Neuroblastoma/Glioblastoma Derived Oncogene Homolog,MLN 19,CD340,Tyrosine kinase-type cell surface receptor HER2,Receptor tyrosine-protein kinase erbB-2,ERBB2,MLN19,Proto-oncogene Neu,V-Erb-B2 Avian Erythro
Number of Launched Drugs:28
Number of Drugs in Clinical Trials:147
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
HE2-HF256 Human FITC-Labeled Human Her2 / ErbB2 Protein, Fc Tag
HE2-HF256-structure
HE2-HF256-sds
HE2-HP2E3 Human PE-Labeled Human Her2 / ErbB2 Protein, His Tag (Site-specific conjugation)
HE2-HP2E3-structure
HE2-H52H9 Human Human Her2 / ErbB2 (23-510) Protein, His Tag (MALS verified)
HE2-H52H9-structure
HE2-H52H9-sds
HE2-H52H3 Human Human Her2 / ErbB2 (S310Y) Protein, His Tag (MALS verified)
HE2-H52H3-structure
HE2-H52H3-sds
HE2-H52H2 Human Human Her2 / ErbB2 (S310F) Protein, His Tag
HE2-H52H2-structure
HE2-H52H2-sds
MBS-K006 Human Human HER2-coupled Magnetic Beads
HE2-H52H4 Human Human Her2 / ErbB2 (498-648) Protein, His Tag
HE2-H52H4-structure
HE2-H52H4-sds
HE2-HF224 Human FITC-Labeled Human Her2 / ErbB2 Protein, His Tag
HE2-HF224-structure
HE2-HF224-sds
HE2-H5255 Human Human Her2 / ErbB2 Protein, Mouse IgG2a Fc Tag (MALS verified)
HE2-H5255-structure
HE2-H5255-sds
HE2-C82E3 Cynomolgus Biotinylated Cynomolgus Her2 / ErbB2 Protein, His,Avitag™ (MALS verified)
HE2-C82E3-structure
HE2-C82E3-sds
HE2-H5212 Human Human Her2 / ErbB2 Protein, Tag Free
HE2-H5212-structure
HE2-H5212-sds
HE2-C52Hb Cynomolgus Cynomolgus Her2 / ErbB2 Protein, His Tag (MALS verified)
HE2-C52Hb-structure
HE2-C52Hb-sds
EHH-V1 Human ELISA Assay Kit for Anti-HER-2 h-mAb in Human Serum
EHM-V1 Mouse ELISA Assay Kit for Anti-HER-2 h-mAb in Mouse Serum
EHC-V1 Monkey ELISA Assay Kit for Anti-HER-2 h-mAb in Monkey Serum
HE2-H82E2 Human Biotinylated Human Her2 / ErbB2 Protein, His,Avitag™
HE2-H82E2-structure
HE2-H82E2-sds
HE2-H525x Human Human Her2 / ErbB2 (23-450) Protein, Fc Tag
HE2-H525x-structure
HE2-H525x-sds
HE2-H822R Human Biotinylated Human Her2 / ErbB2 Protein, His Tag, ultra sensitivity (primary amine labeling, long spacer)
HE2-H822R-structure
HE2-H822R-sds
HE2-H5287 Human Human Her2 / ErbB2 Protein, Strep Tag
HE2-H5287-structure
HE2-H5287-sds
ER2-M5220 Mouse Mouse Her2 / ErbB2 Protein, His Tag
ER2-M5220-structure
ER2-M5220-sds
HE2-H5253 Human Human Her2 / ErbB2 Protein, Fc Tag
HE2-H5253-structure
HE2-H5253-sds
HE2-H5225 Human Human Her2 / ErbB2 Protein, His Tag (MALS verified)
HE2-H5225-structure
HE2-H5225-sds

Part of Bioactivity data

HE2-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Her2, His Tag (Cat. No. HE2-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

Protocol
HE2-HF224-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-Her2 CAR-293 were stained with 100 μL of 1 μg/mL of FITC-Labeled Human Her2, His Tag (Cat. No. HE2-HF224) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

Protocol
HE2-H82E2-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human Her2, His,Avitag (Cat. No. HE2-H82E2) immobilized on SA Chip can bind Herceptin® with an affinity constant of 17 pM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol
HE2-H5225-SPR
Human_FcRn_Heterodimer_Protein_SPR

Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol

Customer Reviews

Synonym Name

ERBB2,CD340,HER-2/neu,HER2,MLN19,NEU,NGL,TKR1

Background

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Trastuzumab/Hyaluronidase Approved Genentech Inc Herceptin Hylecta United States Breast Neoplasms Genentech Inc 2019-02-28 Breast Neoplasms Details
Trastuzumab biosimilar (Allergan/Amgen) ABP-980 Approved Synthon Kanjinti United States Breast Neoplasms; Stomach Neoplasms Amgen Inc 2018-05-16 Stomach Neoplasms; Breast Neoplasms Details
Trastuzumab biosimilar (Biocon/Mylan) Bmab-200; Myl-1401O; HerMyl-1401O Approved Biocon, Mylan Nv CANMAb, Ogivri, Zedora, Hertraz EU Breast Neoplasms; Stomach Neoplasms Mylan Sas 2013-01-01 Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms Details
Trastuzumab/Pertuzumab RO-7198574; RG-6264 Approved F. Hoffmann-La Roche Ltd Phesgo EU Breast Neoplasms Roche Registration Gmbh 2020-06-29 Breast Neoplasms Details
Trastuzumab biosimilar (Biocad) BCD-022 Approved Biocad HERtiCAD Russian Federation Breast Neoplasms Biocad 2016-01-01 Breast Neoplasms Details
Trastuzumab biosimilar (Intas Pharmaceuticals) Approved Intas Biopharmaceuticals Breast Neoplasms Details
Trastuzumab biosimilar (Reliance Life Sciences) R-TPR-016 Approved Reliance Life Sciences TrastuRel India Breast Neoplasms Reliance Life Sciences 2015-01-01 Breast Neoplasms Details
Trastuzumab biosimilar (Pfizer) PF-5280014; PF-05280014 Approved Pfizer Inc Trazimera Japan Breast Neoplasms; Stomach Neoplasms Pfizer Inc 2018-07-26 Stomach Neoplasms; Breast Neoplasms Details
Trastuzumab biosimilar (Shanghai Henlius Biotech) HLX-02 Approved Shanghai Henlius Biotech Co Ltd Zercepac, 汉曲优 Mainland China Breast Neoplasms; Stomach Neoplasms Shanghai Henlius Biopharmaceuticals Co Ltd 2020-07-27 Stomach Neoplasms; Breast Neoplasms Details
Trastuzumab biosimilar (Dr. Reddy's Laboratories) Approved Dr. Reddy’S Laboratories Ltd Hervycta India Breast Neoplasms Dr. Reddy’S Laboratories Ltd 2018-07-26 Breast Neoplasms Details
Trastuzumab biosimilar (Zydus) Approved Zydus Cadila Vivitra India Breast Neoplasms Zydus Cadila 2016-01-01 Breast Neoplasms Details
Trastuzumab biosimilar (Samsung Bioepis) SB-3; AMT-901 Approved Samsung Bioepis Samfenet, Ontruzant United States Breast Neoplasms; Stomach Neoplasms Samsung Bioepis Co Ltd 2017-11-15 Stomach Neoplasms; Breast Neoplasms Details
Trastuzumab biosimilar (AXXO) Approved Axxo Breast Neoplasms Details
Pyrotinib Maleate HTI-1001; SHR-1258; BLTN Approved 艾瑞妮 Mainland China Breast Neoplasms Jiangsu Hengrui Medicine Co Ltd 2018-08-12 Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Breast Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Trastuzumab biosimilar (AryoGen Pharmed) Approved Aryogen Biopharma AryoTrust Stomach Neoplasms; Breast Neoplasms Details
Trastuzumab R-597; RG-597; MKC-454; RO45-2317; huMAb4D5-8; Anti-HER2/neu-MAb Approved Genentech Inc 赫赛汀, Herceptin Mainland China Stomach Neoplasms Roche Pharma (Schweiz) Ag 1998-09-25 Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Urologic Neoplasms; Adenocarcinoma Details
Dacomitinib PF-299; PF-804; PF-299804; PF-00299804; PF-00299804-3; PF-00299804-03 Approved Pfizer Inc Vizimpro Mainland China Carcinoma, Non-Small-Cell Lung Pfizer Europe Ma Eeig 2018-09-27 Solid tumours; Head and Neck Neoplasms; Neoplasms; Liver Diseases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Disitamab Vedotin RC-48-ADC; RC48-ADC; RC-48 Approved RemeGen Co Ltd 爱地希 Mainland China Carcinoma, Transitional Cell RemeGen Co Ltd 2021-06-08 Solid tumours; Biliary Tract Neoplasms; Genital Diseases, Female; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Genital Neoplasms, Female; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Lapatinib Ditosylate Hydrate GW-2016; GW-572016; GW-572016F Approved Novartis Pharma Ag, Glaxosmithkline Plc Tykerb/Tyverb, 泰立沙, Tykerb, Tyverb Mainland China Breast Neoplasms Glaxosmithkline Ag 2007-03-13 Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms Details
Pertuzumab R-1273; RG-1273; RO-4368451; rhuMab-2C4; RO-4368451-F01 Approved Genentech Inc Perjeta, Omnitarg Mainland China Breast Neoplasms Roche Pharma (Schweiz) Ag 2012-06-08 Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Neoplasms, Unknown Primary; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Inetetamab CMAB-302 Approved Shanghai Cp Guojian Pharmaceutical Co Ltd Cipterbin, 赛普汀 Mainland China Breast Neoplasms Shanghai Cp Guojian Pharmaceutical Co Ltd 2020-06-17 Breast Neoplasms Details
Margetuximab MGAH-22 Approved Macrogenics Margenza United States Breast Neoplasms Macrogenics Inc 2020-12-16 Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Afatinib Dimaleate BIBW-2992; BIBW-2992-MA2 Approved C.H. Boehringer Sohn Ag & Co. Kg 吉泰瑞, Tovok, Giotrif, Gilotrif, Tomtovok Mainland China Carcinoma, Non-Small-Cell Lung Boehringer Ingelheim International Gmbh 2013-07-12 Head and Neck Neoplasms; Rhabdomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Neoplasms; Neuroectodermal Tumors; Liver Diseases; Endometriosis; Breast Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma Details
Neratinib Maleate CAN-030; HKI-272; PF-0528767; WAY-179272; PB-272 Approved Pfizer Pharmaceuticals Ltd (China) Nerlynx, 贺俪安 Mainland China Breast Neoplasms Excella Gmbh & Co Kg 2017-07-17 Solid tumours; Glioblastoma; Breast Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ado-trastuzumab emtansine RG-3502; R-3502; T-DM1; PRO-132365; RO-5304020 Approved Genentech Inc Kadcyla, 赫赛莱 Mainland China Breast Neoplasms Roche Pharma (Schweiz) Ag 2013-02-22 Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Trastuzumab emtansine (Zydus Cadila) ZRC-3256 Approved Zydus Cadila Ujvira India Breast Neoplasms Zydus Cadila 2021-05-24 Breast Neoplasms Details
Osimertinib Mesylate AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 Approved Astrazeneca Pharmaceutical Co Ltd 泰瑞沙, Tagrisso Mainland China Carcinoma, Non-Small-Cell Lung Astrazeneca Ab 2015-11-13 Solid tumours; Carcinoma, Bronchogenic; Carcinoma; Thoracic Neoplasms; Bronchial Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
Fam-trastuzumab deruxtecan DS-8201a; DS-8201 Approved Daiichi Sankyo Co Ltd Enhertu EU Breast Neoplasms Daiichi Sankyo Europe Gmbh 2019-12-20 Solid tumours; Ovarian Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms, Glandular and Epithelial; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Endometrioid Details
Tucatinib ARRY-380; ONT-380; MK-7119 Approved Array Biopharma Tukysa EU Breast Neoplasms Seagen Netherlands Bv 2020-04-17 Solid tumours; Stomach Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
Trastuzumab biosimilar (Celltrion) CT-P6; CT-P06 Approved Celltrion Herzuma United States Breast Neoplasms Celltrion Inc 2014-01-01 Stomach Neoplasms; Breast Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) HS-022 Phase 1 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Breast Neoplasms Details
Trastuzumab biosimilar (BioIntegrator) BI-Mab-03 Phase 1 Clinical Biointegrator Breast Neoplasms Details
Lapuleucel-T BA-7072; DN-2402; APC-8024 Phase 2 Clinical Dendreon Uk Ltd Carcinoma, Transitional Cell; Urogenital Neoplasms Details
DZD-1516 DZD-1516 Phase 1 Clinical Dizal (Jiangsu) Pharmaceutical Co Ltd Breast Neoplasms Details
AU-101 AU-101 Phase 2 Clinical Aurora Biopharma Glioblastoma; Osteosarcoma; Breast Neoplasms Details
Zenocutuzumab MCLA-128 Phase 2 Clinical Merus Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CIDeCAR Phase 1 Clinical Bellicum Pharmaceuticals, National Cancer Institute Osteosarcoma Details
Puvitinib Phase 1 Clinical Suzhou Teligene Ltd Solid tumours Details
Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) Phase 1 Clinical Baylor College Of Medicine, The Hospital For Sick Children, Texas Children'S Hospital, The Methodist Hosp Research Institute Sarcoma Details
68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) Phase 1 Clinical Universite Libre De Bruxelles Breast Neoplasms Details
BAT-8001 BAT-8001 Phase 3 Clinical Bio-Thera Solutions Ltd Solid tumours; Breast Neoplasms Details
NeuCeptin NeuCeptin Phase 1 Clinical Neuclone, Serum Institute Of India Stomach Neoplasms; Breast Neoplasms Details
HLX-22 AC-101; HLX-22 Phase 2 Clinical Shanghai Henlius Biotech Co Ltd Solid tumours; Stomach Neoplasms; Breast Neoplasms Details
MT-5111 MT-5111 Phase 1 Clinical Molecular Templates Solid tumours; Neoplasms Details
HER.CAR-CMV-specific-CTLs HER.CAR-CMV-specific-CTLs Phase 1 Clinical Baylor College Of Medicine Glioblastoma Details
AMX-3009 Maleate AMX-3009; AMX3009马来酸 Phase 1 Clinical Anrun Medicine Technology (Suzhou) Co Ltd Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms Details
Varlitinib Ditosylate QBT-01; ARRY-543; SPS-4370; ASLAN-001; ARRY-334543 Phase 3 Clinical Array Biopharma Biliary Tract Neoplasms; Neoplasms; Pancreatic Neoplasms; Bile Duct Neoplasms Details
Autologous-HER2-specific-T-cells Autologous-HER2-specific-T-cells Phase 1 Clinical Baylor College Of Medicine Sarcoma Details
MP-0274 DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 Phase 1 Clinical Molecular Partners Ag Neoplasms Details
Iodine-131-SGMIB anti-HER2 monoclonal antibody 131I-SGMIB-anti-HER2-VHH1; Iodine-131-SGMIB-anti-HER2-VHH1; CAM-H2; [131I]-SGMIB Anti-HER2-VHH1 Phase 2 Clinical Camel-Ids Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms Details
KSP-910638-G KSP-910638G; KSP-910638-G Phase 1 Clinical University Of Michigan Gastrointestinal Neoplasms Details
TAC01-HER2 TAC01-HER2 Phase 2 Clinical Triumvira Immunologics Solid tumours Details
AIP-303 AIP-303 Phase 2 Clinical Advanced Imaging Projects Breast Neoplasms Details
GB-235 GB-235 Phase 1 Clinical Genor Biopharma Co Ltd Breast Neoplasms Details
SSGJ-612 SSGJ-612 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours Details
GQ-1001 GQ-1001 Phase 1 Clinical GeneQuantum Healthcare (Suzhou) Co Ltd Solid tumours; Stomach Neoplasms; Breast Neoplasms Details
trastuzumab biosimilar (Hetero) Ado-Trastuzumab biosimilar (Hetero) Phase 3 Clinical Hetero Drugs Neoplasms Details
ADXS-31164 ADXS-HER2; ADXS-31164; ADXS-cHER2; ADXS31-164 Phase 2 Clinical University Of Pennsylvania Solid tumours; Osteosarcoma Details
Recombinant anti-HER2 humanized monoclonal antibody complex B-002 Phase 1 Clinical Shanghai Pharmaceuticals Holding Co Ltd Breast Neoplasms Details
Pertuzumab biosimilar(SL Pharma/Combio) Phase 1 Clinical Beijing Sl Pharmaceutical Co Ltd, Beijing Kangming Bio New Drug Development Co Ltd Inflammatory Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
[89Zr]-Df-Trastuzumab Phase 1 Clinical University Of Alabama At Birmingham Breast Neoplasms Details
Trastuzumab conjugate (BioIntegrator) BI-CON-02 Phase 1 Clinical Biointegrator Breast Neoplasms Details
IBPM002BZ (Inbiopro Solutions) IBPM-002BZ Clinical Inbiopro Solutions Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms Details
TGFBeta-resistant-HER2-EBV-CTLs TGFBeta-resistant-HER2-EBV-CTLs Phase 1 Clinical Baylor College Of Medicine Neoplasms Details
ETBX-021 ETBX-021 Phase 2 Clinical Nantbioscience, Etubics Corporation Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) Phase 1 Clinical National Cancer Institute Neoplasms Details
Sapitinib AZD-8931 Phase 2 Clinical Astrazeneca Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis Details
Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Research Institute Central Nervous System Neoplasms Details
Pertuzumab biosimilar (Beijing SL) KM-118; KM118 Phase 1 Clinical Breast Neoplasms Details
SHR-A1811 SHR-A1811 Phase 2 Clinical Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Timigutuzumab GT-Mab-7.3-GEX Phase 1 Clinical Glycotope Solid tumours; Stomach Neoplasms; Breast Neoplasms Details
Epertinib S-222611 Phase 2 Clinical Shionogi & Co Ltd Neoplasms Details
HER2/neu peptide vaccine (Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) Phase 2 Clinical Fred Hutchinson/University Of Washington Cancer Consortium Breast Neoplasms Details
Pertuzumab biosimilar (CinnaGen) Phase 3 Clinical Breast Neoplasms Details
BMS-986186 FS-102; BMS-986186 Phase 1 Clinical F-Star Solid tumours; Stomach Neoplasms; Breast Neoplasms Details
HER2(EQ)BBzeta/CD19 T cells (City of Hope) Phase 1 Clinical Mustang Bio, City Of Hope National Medical Center Glioma Details
Recombinant anti-HER2 antibody (Anke Biotech) Phase 3 Clinical Anhui Anke Biotechnology (Group) Co Ltd Breast Neoplasms Details
Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Breast Neoplasms Details
KSP-QRH-E3-IRDye800 Phase 1 Clinical University Of Michigan Cholangiocarcinoma Details
HER-2 Specific CAR T Cell Phase 1 Clinical Ependymoma Details
99m-Tc labeled anti-HER2 single domain antibody (NanoMab) 99mTc-NM-02 Phase 1 Clinical Nanomab Technology Ltd Breast Neoplasms Details
BDC-1001 BDC-1001 Phase 2 Clinical Bolt Biotherapeutics Solid tumours Details
Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) Phase 1 Clinical Qilu Pharmaceutical Co Ltd Breast Neoplasms Details
Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) Phase 1 Clinical Shenzhen Main Luck Pharmaceuticals Inc Breast Neoplasms Details
IMM-2902 IMM-2902 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours Details
anti-HER2 ADC (Pfizer) PF-06804103 Phase 1 Clinical Pfizer Inc Breast Neoplasms Details
Trastuzumab biosimilar (BioXpress Therapeutics) BX-2318 Clinical Bioxpress Therapeutics Sa Breast Neoplasms Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
[18F]GE-226 ABY-002; ABY-025; ABY-0125; 68GaABY025; GE-226; [68Ga]-ABY-025; GE-226-[18F]; [111]In-ABY-025; ABY-025-[68Ga]; ABY-025-[111In]; Gallium-68-ABY-025; Indium-111-ABY-025; Fluorine-18-GE-226 Phase 3 Clinical Affibody Breast Neoplasms Details
Trastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma) DA-3111; DMB-3111 Phase 1 Clinical Meiji Seika Pharma, Dong-A Pharmaceutical Co Ltd Stomach Neoplasms; Breast Neoplasms Details
HER2 cancer vaccine (BioLife Science) PEV-6; PEV-6A; IMU-131 Phase 2 Clinical Pevion Biotech Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma Details
TPIV-100 (TapImmune) TPIV-100 Phase 2 Clinical Mayo Clinic Breast Neoplasms Details
Tesevatinib KD-019; KD-020; XL-647; EXEL-7647 Phase 3 Clinical Exelixis Inc Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Carcinoma, Non-Small-Cell Lung; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis Details
Multi-epitope HER2 peptide vaccine (Mayo Clinic) Phase 1 Clinical Mayo Clinic Breast Neoplasms Details
Selatinib Ditosilate QLNC-120 Phase 2 Clinical Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd Stomach Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
IBPM003TZ (Inbiopro Solutions) IBPM-003TZ Clinical Inbiopro Solutions Breast Neoplasms Details
PB-357 PB-357 Phase 1 Clinical Pfizer Inc Neoplasms Details
BCD-147 BCD-147 Phase 1 Clinical Biocad Details
MB-103 MB-103 Phase 1 Clinical Mustang Bio, City Of Hope National Medical Center Glioblastoma; Brain metastases Details
Recombinant human ErbB3 fragment vaccine (Zensun) rhErbB3-f Phase 1 Clinical Zensun (Shanghai) Sci&Tech Co Ltd Neoplasms Details
JRF-103 JRF103; JRF-103 Phase 2 Clinical Shenzhen Jinrui Foundation Biotechnology Co Ltd Solid tumours Details
89Zr-ss-Pertuzumab Phase 1 Clinical Genentech Inc Breast Neoplasms; Metastatic breast cancer Details
AU-105 AU-105 Phase 2 Clinical Aurora Biopharma Glioblastoma Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pertuzumab biosimilar (Hengrui Pharma) SHR-1309 Phase 1 Clinical Metastatic breast cancer Details
MX-402 MX-402 Phase 1 Clinical Medvax Technologies Stomach Neoplasms Details
Trastuzumab biosimilar (Tanvex Biopharma) TX-05 Phase 3 Clinical Tanvex Biopharma Breast Neoplasms Details
Trastuzumab biosimilar (NeuClone/Serum Institute of India) Phase 1 Clinical Serum Institute Of India, Neuclone Stomach Neoplasms; Breast Neoplasms Details
RG-6148 RG-6148; DHES-0815A Phase 1 Clinical F. Hoffmann-La Roche Ltd Breast Neoplasms Details
CT-0508 Phase 1 Clinical Carisma Therapeutics Inc Carcinoma, Ductal; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Digestive System Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Inflammatory Breast Neoplasms; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms; Head and Neck Neoplasms; Solid tumours Details
BAT1006 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
KY-1701 KY-1701 Phase 1 Clinical Jiangsu Kanion Pharmaceutical Co Ltd Breast Neoplasms Details
Recombinant humanized anti-HER2 antibody (Hisun Pharma) Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Breast Neoplasms Details
Pertuzumab（Hisun Pharm） HS-627; HS627 Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd Breast Neoplasms Details
Coprelotamab GB-221 Phase 3 Clinical Genor Biopharma Co Ltd Breast Neoplasms Details
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) Phase 1 Clinical Hefei Hankemab Biotechnology Co Ltd Solid tumours Details
DP-303c DP-303c; DP303c Phase 2 Clinical Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd Solid tumours; Ovarian Neoplasms; Stomach Neoplasms Details
IAH-0968 IAH-0968; IAH0968 Phase 2 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours Details
Pertuzumab(Jushi Biopharmaceutical ) Phase 1 Clinical Jushi Biopharmaceutical Co Ltd Breast Neoplasms; Metastatic breast cancer Details
FCN-411 FCN-411 Phase 1 Clinical Shanghai Fosun Pharmaceutical (Group) Co Ltd Carcinoma, Non-Small-Cell Lung Details
GB-251 GB-251; NBT-828; GB221-NBT828 ADC-1 Phase 1 Clinical Genor Biopharma Co Ltd, Newbio Therapeutics Inc Breast Neoplasms; Metastatic breast cancer Details
Trastuzumab biosimilar (United BioPharma) UB-921 Phase 1 Clinical United Biopharma Inc Breast Neoplasms Details
Trastuzumab biosimilar (Alteogen) ALT-L2; ALT-02; QL-1701 Phase 3 Clinical Alteogen Inc Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms Details
Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) LZM-005 Phase 1 Clinical Livzon Pharmaceutical Group Inc Breast Neoplasms Details
Pertuzumab biosimilar (CTTQ) TQB-2440 Phase 3 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Breast Neoplasms Details
BB-1701 BB-1701 Phase 1 Clinical Baili Sikang Biomedicine (Hangzhou) Co Ltd Solid tumours Details
AE-37/GP-2 vaccine AE-37 (Generex Biotechnology Corporation) Phase 2 Clinical Generex Biotechnology Corp Triple Negative Breast Neoplasms; Breast Neoplasms Details
HER2.taNK NK-92/5.28.z Phase 1 Clinical Nantkwest Inc Glioblastoma Details
99mTc-HE3-G3 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3 Tomsk National Research Medical Center Of The Russian Academy Of Sciences Details
99mTc-HPArk2 99mTc-HPArk2; 99-mTc-HPArk-2 Phase 1 Clinical Peking Union Medical College Hospital Breast Neoplasms Details
SSGJ-705 SSGJ-705 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours Details
EX-101 EX-101; EX101 Phase 1 Clinical Guangzhou ASM Biomedical Technology Co Ltd Solid tumours Details
RG-6194 RG-6194; BTRC-4017A Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) Phase 2 Clinical University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune Breast Neoplasms Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) Phase 1 Clinical Sichuan University Peritoneal Neoplasms Details
DB-1303 DB-1303 Phase 2 Clinical Duality Biologics Co Ltd Solid tumours Details
Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) SIBP-01 Phase 3 Clinical Shanghai Institute Of Biological Products Co Ltd Stomach Neoplasms; Breast Neoplasms Details
Pertuzumab biosimilar() XZP-KM118 Phase 1 Clinical Xuanzhu (Shijiazhuang) Biotechnology Co Ltd Breast Neoplasms Details
XZP-5209 XZP-5209 Phase 1 Clinical Xuanzhu (Shijiazhuang) Biotechnology Co Ltd Carcinoma, Non-Small-Cell Lung Details
SSGJ-706 SSGJ-706 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
HL-02 HL-02 Phase 3 Clinical Hualan Genetic Engineering Co Ltd Breast Neoplasms Details
Trastuzumab biosimilar (Hualan Biological Engineering) Phase 1 Clinical Hualan Genetic Engineering Co Ltd Stomach Neoplasms; Breast Neoplasms Details
TAS-0728 TPC-107; TAS-0728 Details
BAY-2927088 BAY-2927088; BAY2927088 Phase 1 Clinical Bayer Healthcare Company Ltd, Bayer Ag Carcinoma, Non-Small-Cell Lung Details
Anbenitamab KN-026 Phase 3 Clinical Suzhou Alphamab Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms Details
Cinrebafusp alfa PRS-343 Phase 2 Clinical Pieris Pharmaceuticals Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms Details
Fidasimtamab IBI-315 Phase 1 Clinical Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
99mTc- ADAPT6 99mTc- ADAPT6; ADAPT6; SNA-018 Phase 1 Clinical Uppsala University, Kth Royal Institute Of Technology Breast Neoplasms Details
TAA-013 TAA-013 Phase 3 Clinical Tot Biopharm Co Ltd Breast Neoplasms Details
Pertuzumab biosimilar (Shanghai Henlius Biotech) HLX-11 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Breast Neoplasms Details
A-166 A-166 Phase 2 Clinical Sichuan Kelun Pharmaceutical Co Ltd Lung Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Urologic Neoplasms; Carcinoma, Mucoepidermoid; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Urinary Bladder Neoplasms; Mouth Neoplasms; Lip Neoplasms; Laryngeal Neoplasms; Tonsillar Neoplasms; Uterine Cervical Neoplasms; Tongue Neoplasms; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Skin Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Rare Diseases; Esophageal Neoplasms; Cystadenocarcinoma, Mucinous; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms Details
Hemay-022 Hemay-022 Phase 3 Clinical Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd Breast Neoplasms Details
ARX-788 ARX-788; NCB-001 Phase 3 Clinical Ambrx Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms Details
ALT-P7 HM2-MMAE; ALT-P7 Phase 1 Clinical Alteogen Inc Stomach Neoplasms; Breast Neoplasms Details
Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated ZV0203; ZV203 Phase 1 Clinical Zhejiang Hisun Pharmaceutical Co Ltd, Zhejiang Zova Biotherapeutics Inc, Concortis Biosystems Corp Solid tumours Details
NJH-395 NJH-395 Phase 1 Clinical Novartis Pharma Ag Neoplasms Details
ACE-1702 ACE-1702 Phase 1 Clinical Acepodia Taiwan Subsidiary Solid tumours; Stomach Neoplasms; Metastatic breast cancer; Neoplasm Metastasis Details
BAY-2701439 BAY-2701439 Phase 1 Clinical Bayer Ag Neoplasms Details
Sunvozertinib DZD-9008 Phase 2 Clinical Dizal (Jiangsu) Pharmaceutical Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung Details
ZW-49 ZW-49 Phase 1 Clinical Zymeworks Inc Stomach Neoplasms; Neoplasms; Breast Neoplasms Details
Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) HS-630; HS630 Phase 1 Clinical Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd Breast Neoplasms Details
Pirotinib Hydrochloride KBP-5209 Phase 2 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Trastuzumab biosimilar(Aprogen/Nichi-Iko) AP-06 Phase 3 Clinical Aprogen, Nichi-Iko Pharmaceutical Co Ltd Breast Neoplasms Details
SHR-A1201 SHR-A1201 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Breast Neoplasms Details
Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) B-003 (Shanghai Pharma) Phase 1 Clinical Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Pharmaceuticals Holding Co Ltd Breast Neoplasms Details
MBS-301 MBS-301 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours; Stomach Neoplasms; Breast Neoplasms Details
M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) M-802 Phase 1 Clinical Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms Details
Trastuzumab duocarmazine SYD-985 Phase 3 Clinical Synthon Solid tumours; Stomach Neoplasms; Breast Neoplasms; Endometrial Neoplasms Details
Zanidatamab ZW-25 Phase 3 Clinical Zymeworks Inc Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms Details
LCB14-0110 FS-1502; LCB14-0110 Phase 2 Clinical Legochembio Solid tumours; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
SBT-6050 SBT-6050; SBT6050 Phase 2 Clinical Silverback Therapeutics Inc Solid tumours; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BDTX-189 BDTX-189 Phase 2 Clinical Black Diamond Therapeutics Solid tumours Details
MRG-002 MRG-002 Phase 2 Clinical Shanghai Miracogen Inc Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
ARV-471 ARV-471 Phase 2 Clinical Arvinas Inc Breast Neoplasms Details
HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) GLSI-100 Phase 3 Clinical Antigen Express Inc, Norwell Inc Breast Neoplasms Details
Larotinib Mesylate Z-650 Phase 3 Clinical Guangdong Dongyangguang Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma Details
Recombinant anti-HER2 antibody-Tub114 DAC-001; DX126-262 Phase 2 Clinical Hangzhou Dac Biotech Company Ltd Stomach Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
ZN-A-1041 ZN-A-1041 Phase 1 Clinical Suzhou Zanrong Pharmaceutical Technology Co Ltd Solid tumours; Breast Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap